Search results for "lcsh:RM1-950"

showing 10 items of 252 documents

Long-Term Efficacy of Maintenance Therapy for Multiple Myeloma: A Quantitative Synthesis of 22 Randomized Controlled Trials

2018

We aimed to quantitatively synthesize data from randomized controlled trials (RCTs) concerning maintenance for multiple myeloma (MM). We searched electronic literature databases and conference proceedings to identify relevant RCTs. We selected eligible RCTs using predefined selection criteria. We conducted meta-analysis comparing maintenance containing new agents and conventional maintenance, and subgroup analysis by transplantation status and mainstay agent as well. We performed trial sequential analysis (TSA) to determine adequacy of sample size for overall and subgroup meta-analyses. We performed network meta-analysis (NMA) to compare and rank included regimens. A total of 22 RCTs involv…

Oncologymedicine.medical_specialtySubgroup analysismaintenancelaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialMaintenance therapylawInternal medicinemedicinePharmacology (medical)030212 general & internal medicinenetwork meta-analysisOriginal ResearchLenalidomidePharmacologybusiness.industrylcsh:RM1-950Hazard ratioConfidence intervalmultiple myelomameta-analysisTransplantationtrial-sequential analysislcsh:Therapeutics. Pharmacology030220 oncology & carcinogenesisMeta-analysisbusinessmedicine.drugFrontiers in Pharmacology
researchProduct

Post-therapeutic lymphedema in breast cancer

2019

Introductions. Lymphedema is an interstitial accumulation of protein-rich lymph fluid, due to the post-therapeutic alteration of lymphatic circulation in the upper limb. The appearance of lymphedema is favoured by a number of risk factors. All of these factors ultimately lead to a process of tissue fibrosis. Materials and methods. This study was carried out in an outpatient regimen, for a period of 12 months, in the kinetotherapy room, using massage elements for lymphatic drainage and kinetotherapy technique. The study group included 15 patients aged 27-65 years.Results and discutions. Patients evaluated the quality of life after surgery based on the physical and mental symptoms, which is w…

Oncologymedicine.medical_specialtybusiness.industrylcsh:RM1-950General Medicinelymphedema010402 general chemistrymedicine.disease01 natural scienceskinetotherapy technique0104 chemical scienceslymphatic drainage massage03 medical and health scienceslcsh:Therapeutics. Pharmacology0302 clinical medicineLymphedemaBreast cancer030220 oncology & carcinogenesisInternal medicinemedicinebusinessBalneo Research Journal
researchProduct

Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy

2014

Francesco Saverio Mennini,1,2 Andrea Marcellusi,1,3 Massimo Andreoni,4 Antonio Gasbarrini,5 Salvatore Salomone,6 Antonio Craxì71Centre for Economic and International Studies (CEIS) – Economic Evaluation and HTA (EEHTA) Faculty of Economics, University of Rome Tor Vergata, Rome, Italy; 2Institute of Leadership and Management in Health, Kingston University, London, UK; 3Department of Demography, University of Rome La Sapienza, Rome, Italy; 4Department of Public Health and Cell Biology, School of Medicine, University of Rome Tor Vergata, Rome, Italy; 5Gastroenterology Division, Catholic University of the Sacred Heart of Rome, School of Medicine, Rome, Italy; 6Department of…

Operations researchHepatitis C virusSettore MED/12 - GASTROENTEROLOGIAEconomics Econometrics and Finance (miscellaneous)forecastcost of illnessmacromolecular substancesmedicine.disease_causeChronic hepatitisEnvironmental healthCost of illnessMedicineHealth policyOriginal Researchlcsh:R5-920business.industryHealth Policylcsh:RM1-950Health services researchvirus diseasesSettore SECS-S/04 - Demografianew HCV treatmentClinicoEconomics and Outcomes Researchlcsh:Therapeutics. Pharmacologychronic hepatitishepatitis Cbusinesslcsh:Medicine (General)ClinicoEconomics and Outcomes Research
researchProduct

MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate

2019

Polo-like kinase (PLK1) has been identified as a potential target for cancer treatment. Although a number of small molecules have been investigated as PLK1 inhibitors, many of which showed limited selectivity. PLK1 harbors a regulatory domain, the Polo box domain (PBD), which has a key regulatory function for kinase activity and substrate recognition. We report on 3-bromomethyl-benzofuran-2-carboxylic acid ethyl ester (designated: MCC1019) as selective PLK1 inhibitor targeting PLK1 PBD. Cytotoxicity and fluorescence polarization-based screening were applied to a library of 1162 drug-like compounds to identify potential inhibitors of PLK1 PBD. The activity of compound MC1019 against the PLK1…

PBD Polo box domainMTD maximal tolerance doseCDC25 cell division cycle 25HIF-1α hypoxia-inducible factor 1 αMST microscale thermophoresisIC50 50% inhibition concentrationMFP M phase promoting factorPARP-1 poly(ADP-ribose) polymerase-10302 clinical medicineFOXO forkhead box ONec-1 necrostatin 1CDC2 cell division cycle protein 2 homologGeneral Pharmacology Toxicology and PharmaceuticsMitotic catastropheCDK cyclin-dependent kinase0303 health sciencesChemistryPolo-like kinaseMono-targeted therapyCell cycleBUBR1 budding uninhibited by benzimidazole-related 1Polo box domain030220 oncology & carcinogenesisPLK1 Polo-like kinaseNecroptosisSpindle damagePLK1IHC immunohistochemistryOriginal articleNecroptosisCell cyclePLK1APC/C anaphase-promoting complex/cyclosomePLK3ABC avidin-biotin complexPI propidium iodide03 medical and health sciencesFBS fetal bovine serumPDB Protein Data BankKd the dissociation constantKinase activity030304 developmental biologyAkt/PKB signaling pathwayCell growthlcsh:RM1-950LC3 light chain 3lcsh:Therapeutics. PharmacologyCancer researchDAPKs death-associated protein kinase3-MA 3-methyladenineDAPI 4′6-diamidino-2-phenylindoleSAC spindle assembly checkpointActa Pharmaceutica Sinica B
researchProduct

Impairment of PGC-1 Alpha Up-Regulation Enhances Nitrosative Stress in the Liver during Acute Pancreatitis in Obese Mice

2020

Acute pancreatitis is an inflammatory process of the pancreatic tissue that often leads to distant organ dysfunction. Although liver injury is uncommon in acute pancreatitis, obesity is a risk factor for the development of hepatic complications. The aim of this work was to evaluate the role of PGC-1&alpha

PGC-1&#9450301 basic medicineobesitymedicine.medical_specialtyAntioxidantacute pancreatitisPhysiologymedicine.medical_treatmentClinical BiochemistryPGC-1αAlpha (ethology)Nitrosative stressliverHepatic ComplicationBiochemistryArticle03 medical and health sciences0302 clinical medicineDownregulation and upregulationInternal medicinemedicineObesityMolecular BiologyLiver injurybusiness.industrylcsh:RM1-950Organ dysfunctionCell BiologyBiología y Biomedicina / Biologíamedicine.diseasenitrosative stressAcute pancreatitislcsh:Therapeutics. Pharmacology030104 developmental biologyEndocrinologyLiver030220 oncology & carcinogenesisPancreatitisAcute pancreatitismedicine.symptombusinessAntioxidants
researchProduct

Pathological Findings in COVID-19 as a Tool to Define SARS-CoV-2 Pathogenesis. A Systematic Review

2021

Introduction: The World Health Organization declared the COVID-19 pandemic in March 2020. COVID-19 still represents a worldwide health emergency, which causesa severe disease that has led to the death of many patients. The pathophysiological mechanism of SARS-CoV-2 determining the tissue damage is not clear and autopsycan be auseful tool to improve the knowledge of this infection and, thus, it can help achieve a timely diagnosis and develop an appropriate therapy. This is an overview of the main post-mortem findings reporting data on the infection effects on several organs.Methods: A systematic literature search was conducted in the PubMed database searching for articles from 1 January to A…

Pathologymedicine.medical_specialtypathological findingThrombotic microangiopathyimmuno-thrombotic microangiopathyAutopsyDisease030204 cardiovascular system & hematologyPathogenesis03 medical and health sciencesautopsy0302 clinical medicinesystematic reviewhyperinflammatory statemedicinepathological findingsPharmacology (medical)Diffuse alveolar damagePathologicalPharmacologyLungSARS-CoV-2business.industrylcsh:RM1-950MicroangiopathyCOVID-19medicine.diseasediffuse alveolar damagelcsh:Therapeutics. Pharmacologymedicine.anatomical_structure030220 oncology & carcinogenesisSystematic ReviewbusinessFrontiers in Pharmacology
researchProduct

A Four-Year Observational Study regarding the Characteristics and Causes of the Ischemic Stroke in Young Adults: one center study report

2020

Introduction. Stroke is the second cause of mortality worldwide, after the ischemic coronary disease, and the first cause of long term-disability. Recent studies report that ischemic stroke (IS) in young patients is increasing in incidence, even though the overall stroke hospitalization rate is decreasing. Stroke in the young, working individuals significantly affects the quality of life (QoL) and also determines an important, negative economic impact by reducing the workforce. Material and method. The aim of this paper is to present the results of a 4-year observational, retrospective study on all patients between 18-49 years, who suffered from acute IS and were admitted and investigated i…

Pediatricsmedicine.medical_specialtybusiness.industrylcsh:RM1-950General Medicine030204 cardiovascular system & hematologyyoung patients03 medical and health scienceslcsh:Therapeutics. Pharmacology0302 clinical medicinedisabilityStudy reportvascular risk factorsIschemic strokeischemic strokemedicineCenter (algebra and category theory)Observational studyYoung adultbusiness030217 neurology & neurosurgerytoast classificationBalneo Research Journal
researchProduct

The Post-Lockdown Era: What Is Next in Italy?

2020

The current outbreak of the COVID-19 infection, which started in December 2019 in Wuhan (China), was declared a pandemic by the World Health Organization (WHO) on the 11th of March, 2020.

Pharmacology2019-20 coronavirus outbreakOpinionCoronavirus disease 2019 (COVID-19)business.industrydiagnosisSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)infectious diseaselcsh:RM1-950COVID-19infectious diseasesVirologymortalitydiagnosilcsh:Therapeutics. PharmacologyautopsyMedicinePharmacology (medical)business
researchProduct

Medicinally Used Asarum Species: High-Resolution LC-MS Analysis of Aristolochic Acid Analogs and In vitro Toxicity Screening in HK-2 Cells

2017

Species of Asarum are used in traditional Chinese medicine and, similar to members of the genus Aristolochia, they contain aristolochic acid analogs (AAAs). These compounds are known for their nephrotoxic and carcinogenic effects. So far, the phytochemistry and nephrotoxicity of species of Asarum is not well studied. A high-resolution LC-MS-based metabolomic approach was used to study the phytochemical variation in medicinally used Asarum species. The cytotoxicity of the samples was assessed using human kidney (HK-2) cells. The majority of samples contained potentially nephrotoxic AAAs, including 9-methoxy aristolactam (AL) IV, AL I, and AL IV. These compounds were present in methanol as we…

PharmacologyAsarumlcsh:Therapeutics. Pharmacologynephrotoxicityaristolactamlcsh:RM1-950Pharmacology (medical)metabolomicsLC-MSFrontiers in Pharmacology
researchProduct

Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system

2019

Primary myelofibrosis (PMF) is a myeloproliferative neoplasm in which clonal proliferation of hematopoietic stem cells and bone marrow fibrosis coexist.1 Patients may eventually die due to leukemic progression, which occurs in up to 20% of cases, or because of cardiovascular comorbidities or cytopenia, which causes susceptibility to infections and bleeding.2 Myelofibrosis diagnosis relies upon the evaluation of several clinical and laboratory criteria suggested by the World Health Organization (WHO) in 2016.3 The major mutations leading to myelofibrosis usually occur in the JAK2, CALR, and MPL genes. However, in almost 10% of the cases, none of the above-mentioned mutations can be detected …

PharmacologyCytopeniamedicine.medical_specialtyRuxolitinibbusiness.industryIPSSruxolitinibprimary myelofibrosilcsh:RM1-950Case ReportGeneral Medicinemedicine.diseaseDiscontinuationPolycythemia veralcsh:Therapeutics. PharmacologyInternational Prognostic Scoring SystemInternal medicinemedicineprimary myelofibrosisMolecular MedicineMyelofibrosisAdverse effectbusinessMyeloproliferative neoplasmmedicine.drugDrugs in Context
researchProduct